Related Experiment Video
Updated: Apr 12, 2026
07:59
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
3.1K
Anti-angiogenesis therapy in gynecologic malignancies
Oncology (Williston Park, N.Y.)
|May 17, 2015
Summary
Bevacizumab, an anti-angiogenic agent, improves survival in advanced cervical cancer, shifting treatment standards. Its use in ovarian and uterine cancers is under investigation, with other agents showing promise.
Area of Science:
- Oncology
- Pharmacology
Background:
- Anti-angiogenic agents are crucial in gynecologic cancer treatment.
- Bevacizumab is approved for advanced cervical and platinum-resistant ovarian cancers.
Purpose of the Study:
- To review the role and efficacy of bevacizumab in gynecologic malignancies.
- To discuss ongoing research and future directions for anti-angiogenic therapies.
Main Methods:
- Literature review of clinical trials and studies on bevacizumab in gynecologic cancers.
- Analysis of treatment outcomes and survival data.
Main Results:
- Bevacizumab significantly improved overall survival in advanced cervical cancer, altering standard care.
- Efficacy in uterine cancer is not yet established, with ongoing early-phase trials.
- Optimal combinations with chemotherapy for ovarian cancer are still being determined.
Conclusions:
- Bevacizumab has demonstrated significant benefit in advanced cervical cancer.
- Further research is needed to define bevacizumab's role in ovarian and uterine cancers.
- Investigational oral anti-angiogenic therapies show promise for gynecologic cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:57Targeted Cancer Therapies
1.8K
1.8K
02:49Cancer Therapies
10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
01:24Regulation of Angiogenesis and Blood Supply
4.0K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
01:10Mechanism of Angiogenesis
7.8K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.8K